RAPP NASDAQ
Credit Risk of going bust: lower than 78% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.03 (down 99.9%), Rapport Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $10.1M against a stock market value of $1.32B.
Distance to default 9.07 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.1M (short-term plus half of long-term), stock volatility 60.2%; Altman Z'' 13.94. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02110
US
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sanchez Ramiro | P-Purchase | 3,600 | $27.35 | 2026-10-23 |
| Silva Paul M | P-Purchase | 3,680 | $27.07 | 2026-10-22 |
| Young Wendy B. | P-Purchase | 3,789 | $26.39 | 2026-10-22 |
| PAUL STEVEN M | P-Purchase | 35,714 | $27.28 | 2026-10-22 |
| MARAGANORE JOHN | P-Purchase | 8,239 | $26.38 | 2026-10-22 |